vimarsana.com
Home
Live Updates
Vir Biotechnology, Inc.: Multiple Abstracts Highlighting Vir Biotechnologys Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024 : vimarsana.com
Vir Biotechnology, Inc.: Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
- Company to present important new data from the Phase 2 SOLSTICE chronic hepatitis delta trial - - Conference call scheduled for June 5, 2024, at 6:00 a.m. ET 12:00 p.m. CEST - Vir Biotechnology
Related Keywords
Clichy ,
France General ,
France ,
Paris ,
Milan ,
Lombardia ,
Italy ,
Snehav Gupta ,
Carey Hwang ,
Carly Scaduto ,
Andrea Cathcart ,
Richard Lepke ,
Tarik Asselah ,
Nasdaq ,
Alnylam Pharmaceuticals Inc ,
University Of Paris ,
Clinical Research ,
Exchange Commission ,
Vir Biotechnology Inc ,
European Association ,
Liver Diseases ,
Senior Vice President ,
Interim Chief Medical ,
Viral Hepatitis ,
Senior Director ,
Clinical Virology ,
Vir Biotechnology ,
Clinical Pharmacology ,
Enhanced Stabilization Chemistry Plus ,
Alnylam Pharmaceuticals ,
Private Securities Litigation Reform Act ,
External Communications ,
Investor Relations ,
Ihr Portfolio ,
vimarsana.com © 2020. All Rights Reserved.